Back to News
Market Impact: 0.3
Becton, Dickinson and Company Q4 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Becton, Dickinson and Company reported higher fiscal fourth-quarter revenue and adjusted earnings. Demand for patient monitoring, biologic drug delivery and other products helped offset a difficult comparison for its Alaris infusion platform; the article provides no figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BDX0.55
More News
- Wells Fargo upgrades Becton Dickinson stock rating on execution
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise